ArticleChembiochem : a European journal of chemical biology2025
Activity Analysis of the P2X Receptor Antagonist PPADS against Signal Transducer and Activator of Transcription Proteins.
Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biaryl Phosphate-Based Inhibitors of the Transcription Factor STAT4.ChemMedChem · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The small molecule PPADS is a P2X receptor antagonist. Analysis of a library of known bioactive compounds in competitive fluorescence polarization-based assays indicates that PPADS and its isomer iso-PPADS also possess activity against members of the signal transducer and activator of transcription (STAT) family of transcription factors, in particular STAT4, STAT5a, and STAT5b. These results are also supported by HTRF assays. PPADS protects STAT4 and STAT5a/STAT5b from thermal degradation in cell lysates to a higher extent than STAT3. Combined data from this article and a previous article suggest that aromatic disulfonate antagonists of P2X receptors might serve as promising starting points for the development of inhibitors of STAT proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.